Close Banner
Section Free  - Video Lectures

05. Prescribing Lithium During Pregnancy: Pharmacokinetics, Dosing, and Monitoring

Published on December 1, 2020 Expired on April 1, 2025

Wendy Marsh, M.D., M.S.

Associate Professor, Director - University of Massachusetts Medical School/UMass Memorial Medical Center

Key Points

  • Management of lithium in pregnancy needs to be rigorous. Use of lithium is not without risks.
  • Use the lowest effective dose.
  • Monitor lithium levels every 3 weeks until Week 34, and then monitor every week.

Free Downloads for Offline Access

  • Free Download Audio File (MP3)
  • Free Download Video (MP4)
  • Free Download Presentation File (PPTX)

Slides and Transcript

Slide 1 of 10

Here I’m going to talk about prescribing and monitoring lithium during pregnancy. So you’ve decided that the risk of a mood episode versus medication exposure is such that it’s worth continuing medication treatment of lithium. Our prescribing and monitoring examples here are going to be for lithium but the concepts can be applied to prescribing other medications for mood in pregnancy as well.

Slide 2 of 10

So the pharmacokinetics of lithium and most other meds change throughout pregnancy. This image here is of the pharmacokinetic changes occurring during pregnancy. It’s an example of the complex biological changes that can influence psychotropic medications and their effects. For example, small to moderate sex differences which exist in drug absorption, distribution, metabolism and elimination may be amplified during pregnancy. And using lithium in this example, there’s increased renal blood flow and associated increasing glomerular filtration rate that may increase the medication’s elimination during pregnancy. Or increase hepatic blood flow may account for increased clearance and decreased concentrations of hepatically metabolized medication during pregnancy.
References:
  • Newport, D. J., Viguera, A. C., Beach, A. J., Ritchie, J. C., Cohen, L. S., & Stowe, Z. N. (2005). Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. American Journal of Psychiatry, 162(11), 2162-2170. 
  • Deligiannidis, K. M., Byatt, N., & Freeman, M. P. (2014). Pharmacotherapy for mood disorders in pregnancy. Journal of Clinical Psychopharmacology, 34(2), 244-255.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 3 of 10

So lithium levels vary throughout pregnancy. Lithium blood levels have been reported to decrease in the first trimester, reach a nadir or lowest point in the second trimester and they may increase in the third trimester. Thus, monitoring of lithium levels needs to be done closely during pregnancy.
References:
  • Wesseloo, R., Wierdsma, A. I., Van Kamp, I. L., Munk-Olsen, T., Hoogendijk, W. J., Kushner, S. A., & Bergink, V. (2017). Lithium dosing strategies during pregnancy and the postpartum period. British Journal of Psychiatry, 211(1), 31-36.

Slide 4 of 10

Remember our treatment in pregnancy principles. Preconception, to have a baseline lithium level, the lowest yet effective dose which maintains euthymia in a patient. If you can gather that, that’s going to be your target in pregnancy. It’s also helpful to have a preconception TSH and renal function levels to compare during pregnancy as the pregnancy progresses. It’s also recommended starting b.i.d. dosing pre-pregnancy with the plan to reduce the amplitude or fluctuations of lithium levels during pregnancy as half of pregnancies are unexpected.
References:
  • Wesseloo, R., Wierdsma, A. I., Van Kamp, I. L., Munk-Olsen, T., Hoogendijk, W. J., Kushner, S. A., & Bergink, V. (2017). Lithium dosing strategies during pregnancy and the postpartum period. British Journal of Psychiatry, 211(1), 31-36.
  • Diav-Citrin, O., Shechtman, S., Tahover, E., Finkel-Pekarsky, V., Arnon, J., Kennedy, D., Erebara, A., Einarson, A., & Ornoy, A. (2014). Pregnancy outcome following in utero exposure to lithium: A prospective, comparative, observational study. American Journal of Psychiatry, 171(7), 785-794.
  • Clark, C. T., & Wisner, K. L. (2018). Treatment of Peripartum bipolar disorder. Obstetrics and Gynecology Clinics of North America, 45(3), 403-417.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 5 of 10

During pregnancy, it’s important to be aware of the pharmacokinetic changes. During pregnancy, lithium clearance increases 30% to 50% due to increased renal blood flow and glomerular filtration rate particularly in the last month of gestation. This causes plasma levels to fall substantially and increases the risk of maternal relapse. At delivery, vascular volume rapidly decreases, and lithium clearance precipitously falls to pre-pregnancy levels. So after birth, we have decrease in vascular volume and a decrease in lithium clearance.
References:
  • Clark, C. T., & Wisner, K. L. (2018). Treatment of Peripartum bipolar disorder. Obstetrics and Gynecology Clinics of North America, 45(3), 403-417.
  • Wesseloo, R., Wierdsma, A. I., Van Kamp, I. L., Munk-Olsen, T., Hoogendijk, W. J., Kushner, S. A., & Bergink, V. (2017). Lithium dosing strategies during pregnancy and the postpartum period. British Journal of Psychiatry, 211(1), 31-36.
  • Newport, D. J., Viguera, A. C., Beach, A. J., Ritchie, J. C., Cohen, L. S., & Stowe, Z. N. (2005). Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. American Journal of Psychiatry, 162(11), 2162-2170.

Slide 6 of 10

So it’s important to follow levels closely in pregnancy and recommendations are often every three weeks for the first part of pregnancy, certainly more often if there’s concern about a mood episode or symptoms coming on or adverse effects may be occurring. And also to anticipate the need to adjust or increase dose during pregnancy to target that effective lithium level. Late in pregnancy, increased frequency of monitoring. After 34 weeks, the goal of monitoring lithium every week to follow for those concentration or plasma level changes.
References:
  • Wesseloo, R., Wierdsma, A. I., Van Kamp, I. L., Munk-Olsen, T., Hoogendijk, W. J., Kushner, S. A., & Bergink, V. (2017). Lithium dosing strategies during pregnancy and the postpartum period. British Journal of Psychiatry, 211(1), 31-36.
  • Newport, D. J., Viguera, A. C., Beach, A. J., Ritchie, J. C., Cohen, L. S., & Stowe, Z. N. (2005). Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. American Journal of Psychiatry, 162(11), 2162-2170.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 7 of 10

And historically, the thought was to hold or to stop the lithium prior to labor with the goal of reducing the risk of neonatal adjustment or floppy baby syndrome. However, the newer proposition is to actually follow that lithium level very closely and to continue dosing as the mother enters the end of pregnancy and into the postpartum time. The reasoning behind this is that we know that maintaining euthymia in the mom benefits both the mom and the infant and this postpartum time is just such a high risk for a mood episode in bipolar disorder. And here, we are with the idea of stopping the lithium abruptly can put the woman at an increased risk itself. And there are some initial data saying that adjustment symptoms in the infant are not looking like they’re associated with ongoing sequelae. Again, these are earlier studies. But these are some of the risks to be weighing as you’re treating a woman going into labor and delivery.
References:
  • Wesseloo, R., Wierdsma, A. I., Van Kamp, I. L., Munk-Olsen, T., Hoogendijk, W. J., Kushner, S. A., & Bergink, V. (2017). Lithium dosing strategies during pregnancy and the postpartum period. British Journal of Psychiatry, 211(1), 31-36.
  • Newport, D. J., Viguera, A. C., Beach, A. J., Ritchie, J. C., Cohen, L. S., & Stowe, Z. N. (2005). Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. American Journal of Psychiatry, 162(11), 2162-2170.

Slide 8 of 10

So also, thoughts on additional monitoring with lithium during pregnancy. Definitely recommend a high-risk OB and getting release of information to communicate with that physician. Obtaining a fetal echocardiogram or level 2 ultrasound at that 16 or 18 weeks’ gestational age. That’s under the purview of the OB. And then monitoring for lithium serum levels as well as TSH, thyroid and renal function as the pregnancy progresses. And don’t forget about interactions with lithium, that medication use can change in pregnancy and there’s increase in lithium levels if the woman starts using NSAIDs or diuretics or ACE inhibitors and then a decrease in lithium levels — Primarily watch for the caffeine. With the sleep disruption and exhaustion that can come with pregnancy, women may be using more caffeine to counteract that.
References:
  • Galbally, M., Roberts, M., Buist, A., & Perinatal Psychotropic Review Group. (2010). Mood stabilizers in pregnancy: a systematic review. Australian & New Zealand Journal of Psychiatry, 44(11), 967-977.
  • Wesseloo, R., Wierdsma, A. I., Van Kamp, I. L., Munk-Olsen, T., Hoogendijk, W. J., Kushner, S. A., & Bergink, V. (2017). Lithium dosing strategies during pregnancy and the postpartum period. British Journal of Psychiatry, 211(1), 31-36.
Free Files
Success!
Check your inbox, we sent you all the materials there.

Slide 9 of 10

Our key points in using lithium in pregnancy. So while management of lithium in pregnancy needs to be rigorous and use of lithium is not without risks, stick to your guiding principles. Our goal is to have the woman doing well, use the lowest effective dose and work with close monitoring for lithium in pregnancy with the guideline of every three weeks until week 34 and then every week after that to assess for your need to adjust dose.

Slide 10 of 10

Free Files
Success!
Check your inbox, we sent you all the materials there.

Learning Objectives:

After completing this activity, the learner will be able to:

  1. Discuss the management of bipolar disorder during pregnancy.
  2. Assess the risks and benefits of pharmacologic treatment, considering the effects on the mother and potential fetal complications.

Original Release Date: 12/01/2020

Review and Re-release Date: 03/01/2024

Expiration Date: 04/01/2025

Expert: Wendy Marsh, M.D.

Medical Editor: Lorena Rodriguez, M.D

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationship(s) to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

  1. View the required educational content provided on this course page.
  2. Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
  3. Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Free Files
Success!
Check your inbox, we sent you all the materials there.
Continue in the website
Instant access modal

Become a Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Member.

2025–26 Psychopharmacology CME Program

Unlock up to 155 CME Credits, including 40 SA CME Credits.